Dr. Richard Scolyer, an Australian pathologist and co-director of Melanoma Institute Australia, was diagnosed with glioblastoma—a highly aggressive and usually terminal brain cancer. He was given less than a year to live.
Instead of conventional therapy, he collaborated with his colleague Prof. Georgina Long to create a first-of-its-kind treatment plan involving:
Combination immunotherapy before surgery (neoadjuvant),
A personalized cancer vaccine tailored to his tumor’s genetic profile.
These approaches were adapted from their successful melanoma immunotherapy research.
Outcome:
Over a year after diagnosis, Scolyer remains cancer-free.
His case is being closely studied as a potential game-changer in brain cancer treatment, especially for glioblastoma, which usually has a 5% five-year survival rate.
Caveats:
The treatment caused serious side effects (seizures, brain swelling).
It's a single case; long-term remission or cure is not confirmed yet.
Clinical trials are likely to follow this model soon.
Instead of conventional therapy, he collaborated with his colleague Prof. Georgina Long to create a first-of-its-kind treatment plan involving:
Combination immunotherapy before surgery (neoadjuvant),
A personalized cancer vaccine tailored to his tumor’s genetic profile.
These approaches were adapted from their successful melanoma immunotherapy research.
Outcome:
Over a year after diagnosis, Scolyer remains cancer-free.
His case is being closely studied as a potential game-changer in brain cancer treatment, especially for glioblastoma, which usually has a 5% five-year survival rate.
Caveats:
The treatment caused serious side effects (seizures, brain swelling).
It's a single case; long-term remission or cure is not confirmed yet.
Clinical trials are likely to follow this model soon.
Dr. Richard Scolyer, an Australian pathologist and co-director of Melanoma Institute Australia, was diagnosed with glioblastoma—a highly aggressive and usually terminal brain cancer. He was given less than a year to live.
Instead of conventional therapy, he collaborated with his colleague Prof. Georgina Long to create a first-of-its-kind treatment plan involving:
Combination immunotherapy before surgery (neoadjuvant),
A personalized cancer vaccine tailored to his tumor’s genetic profile.
These approaches were adapted from their successful melanoma immunotherapy research.
Outcome:
Over a year after diagnosis, Scolyer remains cancer-free.
His case is being closely studied as a potential game-changer in brain cancer treatment, especially for glioblastoma, which usually has a 5% five-year survival rate.
Caveats:
The treatment caused serious side effects (seizures, brain swelling).
It's a single case; long-term remission or cure is not confirmed yet.
Clinical trials are likely to follow this model soon.
0 Σχόλια
0 Μοιράστηκε
22χλμ. Views
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Arabic